Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | GRN | P28799 | 1/20 | 0.32 |
| ▸ | SORT1 | Q99523 | 1/20 | 0.32 |
| ▸ | HRH2 | P25021 | 1/20 | 0.32 |
| ▸ | HRH1 | P35367 | 1/20 | 0.32 |
| ▸ | NOS3 | P29474 | 1/20 | 0.31 |
| ▸ | NOS1 | P29475 | 1/20 | 0.31 |
| ▸ | NOS2 | P35228 | 1/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.30 |
| ▸ | CA2 | P00918 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1414721 | 1.00 | MAPK1 (0.44) | MAPK1GRNSORT1HRH2HRH1 | |
| SCHEMBL30173349 | 1.00 | MAPK1 (0.44) | MAPK1GRNSORT1HRH2HRH1 | |
| Hydrochloric Acid SCHEMBL4683319 | 0.98 | MAPK1 (0.43) | MAPK1GRNSORT1HRH2HRH1 | |
| SCHEMBL16450873 | 0.82 | MAPK1 (0.44) | MAPK1GRNSORT1HRH2HRH1 | |
| SCHEMBL561163 | 0.82 | MAPK1 (0.44) | MAPK1GRNSORT1NOS3NOS1 | |
| SCHEMBL1644294 | 0.82 | MAPK1 (0.44) | MAPK1GRNSORT1NOS3NOS1 | |
| SCHEMBL16450884 | 0.82 | MAPK1 (0.44) | MAPK1GRNSORT1HRH2HRH1 | |
| SCHEMBL241174 | 0.82 | MAPK1 (0.44) | MAPK1GRNSORT1NOS3NOS1 | |
| SCHEMBL30589488 | 0.80 | MAPK1 (0.43) | MAPK1GRNSORT1NOS3NOS1 | |
| Hydrochloric Acid SCHEMBL920374 | 0.80 | MAPK1 (0.43) | MAPK1GRNSORT1NOS3NOS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2480524-A1 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF | Cadila Healthcare Limited (IN) | 2012-08-01 | — | — | EP | disclosed |
| US-20110105485-A1 | Alpha-(N-Sulfonamido)Acetamide Derivatives as Beta-Amyloid Inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2011-05-05 | — | — | US | disclosed |
| WO-2011039781-A1 | PROCESSES FOR THE PREPARATION OF LACOSAMIDE AND INTERMEDIATES THEREOF | CADILA HEALTHCARE LIMITED (IN) | 2011-04-07 | — | — | WO | disclosed |
| US-7786122-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-08-31 | — | — | US | disclosed |
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-04-10 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
| US-7300936-B2 | α-(N-sulfonamido)acetamide derivatives as β-amyloid inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080085894-A1 | ALPHA-(N-SULFONAMIDO)ACETAMIDE DERIVATIVES AS BETA-AMYLOID INHIBITORS | APP, APBA1, BACE1 | MAPK1 1307/4885GRN 336/4885SORT1 730/4885 |
| US-20110105485-A1 | Alpha-(N-Sulfonamido)Acetamide Derivatives as Beta-Amyloid Inhibitors | APP, APBA1, BACE1 | MAPK1 1307/4885GRN 336/4885SORT1 730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.